Cost-effectiveness of prevention and early detection of gastric cancer in Western countries

Lansdorp–Vogelaar, Iris; Meester, Reinier G. S.; Laszkowska, Monika; Alarid‐Escudero, Fernando; Ward, Zachary J.; Yeh, Jennifer M.

doi:10.1016/j.bpg.2021.101735

Cited by 31 publications

(21 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The vast majority of gastric cancer cases present at late disease stage i.e., regional and distant disease in high-income countries. 39 While the balance between benefits, harms and costs of routine screening in low-risk populations is still unclear, 40 the implementation of population-based screening in high-risk regions has shown some promise. 41 Studies have also shown that screening in high-risk sub-populations, e.g.…”

Section: Discussionmentioning

confidence: 99%

The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling study

et al. 2022

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling study

et al. 2022

View full text Add to dashboard Cite

“…The witnessed gaps and inequities call for concerted efforts to lessen the burden of PUD in areas with limited resources. Given the level of technology, expenses, and the expertise required for complications management of PUD, its early detection and prevention seem feasible and cost-effective [ 43 ]. However, further research is required to determine the most suitable strategies for early detection, treatment, and follow-up based on available resources.…”

Section: Discussionmentioning

confidence: 99%

Quality of care of peptic ulcer disease worldwide: A systematic analysis for the global burden of disease study 1990–2019

et al. 2022

View full text Add to dashboard Cite

Background Peptic ulcer disease (PUD) affects four million people worldwide annually and has an estimated lifetime prevalence of 5−10% in the general population. Worldwide, there are significant heterogeneities in coping approaches of healthcare systems with PUD in prevention, diagnosis, treatment, and follow-up. Quantifying and benchmarking health systems’ performance is crucial yet challenging to provide a clearer picture of the potential global inequities in the quality of care. Objective The objective of this study was to compare the health-system quality-of-care and inequities for PUD among age groups and sexes worldwide. Methods Data were derived from the Global Burden of Disease Study 1990–2019. Principal-Component-Analysis was used to combine age-standardized mortality-to-incidence-ratio, disability-adjusted-life-years-to-prevalence-ratio, prevalence-to-incidence-ratio, and years-of-life-lost-to-years-lived-with-disability-into a single proxy named Quality-of-Care-Index (QCI). QCI was used to compare the quality of care among countries. QCI’s validity was investigated via correlation with the cause-specific Healthcare-Access-and-Quality-index, which was acceptable. Inequities were presented among age groups and sexes. Gender Disparity Ratio was obtained by dividing the score of women by that of men. Results Global QCI was 72.6 in 1990, which increased by 14.6% to 83.2 in 2019. High-income-Asia-pacific had the highest QCI, while Central Latin America had the lowest. QCI of high-SDI countries was 82.9 in 1990, which increased to 92.9 in 2019. The QCI of low-SDI countries was 65.0 in 1990, which increased to 76.9 in 2019. There was heterogeneity among the QCI-level of countries with the same SDI level. QCI typically decreased as people aged; however, this gap was more significant among low-SDI countries. The global Gender Disparity Ratio was close to one and ranged from 0.97 to 1.03 in 100 of 204 countries. Conclusion QCI of PUD improved dramatically during 1990–2019 worldwide. There are still significant heterogeneities among countries on different and similar SDI levels.

show abstract

“…Several studies reported that other factors than the extent of severity of AG could be associated with an increased risk of GC, such as the presence of incomplete type IM [28][29][30]53,54]; however, we were not able to provide these data for our population due to the absence of systematic IM subtyping. We did not perform a cost-efficiency analysis for this study in particular, but a recent and nice review summarized the results of studies conducted in this setting, and addressed the pros and cons in the different situations [55].…”

Section: Discussionmentioning

confidence: 99%

Serum Pepsinogens Combined with New Biomarkers Testing Using Chemiluminescent Enzyme Immunoassay for Non-Invasive Diagnosis of Atrophic Gastritis: A Prospective, Multicenter Study

et al. 2022

View full text Add to dashboard Cite

Background: Analysis of serum biomarkers for the assessment of atrophic gastritis (AG), a gastric precancerous lesion, is of growing interest for identification of patients at increased risk of gastric cancer. The aim was to analyze the diagnostic performance of serum pepsinogen testing using another method, chemiluminescent enzyme immunoassay (CLEIA), as well as of other new potential biomarkers. Material and Methods: The sera of patients considered at increased risk of gastric cancer and undergoing upper endoscopy collected in our previous prospective, multicenter study were tested for pepsinogen I (PGI) and II (PGII), interleukin-6 (IL-6), human epididymal protein 4 (HE-4), adiponectin, ferritin and Krebs von den Lungen (KL-6) using the CLEIA. The diagnostic performance for the detection of AG was calculated by taking histology as the reference. Results: In total, 356 patients (162 men (46%); mean age 58.6 (±14.2) years), including 152 with AG, were included. For the detection of moderate to severe corpus AG, sensitivity and specificity of the pepsinogen I/II ratio were of 75.0% (95%CI 57.8–87.9) and 92.6% (88.2–95.8), respectively. For the detection of moderate to severe antrum AG, sensitivity of IL-6 was of 72.2% (95%CI 46.5–90.3). Combination of pepsinogen I/II ratio or HE-4 showed a sensitivity of 85.2% (95%CI 72.9–93.4) for the detection of moderate to severe AG at any location. Conclusion: This study shows that PG testing by CLEIA represents an accurate assay for the detection of corpus AG. Additionally, IL-6 and HE-4 may be of interest for the detection of antrum AG. Mini-abstract: Pepsinogens testing by chemiluminescent enzyme immunoassay is accurate for the detection of corpus atrophic gastritis. IL-6 and HE-4 maybe of interest for the detection of antrum atrophic gastritis.

show abstract

Cost-effectiveness of prevention and early detection of gastric cancer in Western countries

Cited by 31 publications

References 56 publications

The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling study

The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling study

Quality of care of peptic ulcer disease worldwide: A systematic analysis for the global burden of disease study 1990–2019

Serum Pepsinogens Combined with New Biomarkers Testing Using Chemiluminescent Enzyme Immunoassay for Non-Invasive Diagnosis of Atrophic Gastritis: A Prospective, Multicenter Study

Contact Info

Product

Resources

About